• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A potentially serious adverse effect of GLP-1 receptor agonists.

作者信息

Lu Jinmiao, Liu Hao, Zhou Qingtong, Wang Ming-Wei, Li Zhiping

机构信息

Department of Pharmacy, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.

School of Medicine, Ningbo University, Ningbo 315211, China.

出版信息

Acta Pharm Sin B. 2023 May;13(5):2291-2293. doi: 10.1016/j.apsb.2023.02.020. Epub 2023 Mar 2.

DOI:10.1016/j.apsb.2023.02.020
PMID:37250165
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10213739/
Abstract
摘要

相似文献

1
A potentially serious adverse effect of GLP-1 receptor agonists.胰高血糖素样肽-1受体激动剂的一种潜在严重不良反应。
Acta Pharm Sin B. 2023 May;13(5):2291-2293. doi: 10.1016/j.apsb.2023.02.020. Epub 2023 Mar 2.
2
Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.胰岛素-胰高血糖素样肽-1 受体激动剂接力和胰高血糖素样肽-1 受体激动剂一线治疗方案在 2 型糖尿病患者中的随机、开放标签试验研究。
J Diabetes Investig. 2022 Jun;13(6):965-974. doi: 10.1111/jdi.13749. Epub 2022 Feb 8.
3
Glucagon-like peptide-1 receptor action in the vasculature.胰高血糖素样肽-1 受体在血管中的作用。
Peptides. 2019 Jan;111:26-32. doi: 10.1016/j.peptides.2018.09.002. Epub 2018 Sep 15.
4
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
5
Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.高剂量胰高血糖素样肽-1、胰高血糖素样肽-1/葡萄糖依赖性胰岛素释放肽和胰高血糖素样肽-1/胰高血糖素受体激动剂在 2 型糖尿病中的疗效和安全性。
Diabetes Obes Metab. 2022 May;24(5):788-805. doi: 10.1111/dom.14640. Epub 2022 Jan 21.
6
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.胰高血糖素样肽-1及胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的应用
Ann Pediatr Endocrinol Metab. 2017 Mar;22(1):15-26. doi: 10.6065/apem.2017.22.1.15. Epub 2017 Mar 31.
7
The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.短效和长效胰高血糖素样肽-1激动剂在2型糖尿病管理中的价值：艾塞那肽的应用经验
Curr Med Res Opin. 2016;32(1):61-76. doi: 10.1185/03007995.2015.1103214. Epub 2015 Nov 11.
8
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病患者的心血管结局：一项荟萃分析。
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.
9
Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.评估 GLP-1 和胰高血糖素受体双重激动剂介导的偏激动作用。
Biochem Pharmacol. 2020 Oct;180:114150. doi: 10.1016/j.bcp.2020.114150. Epub 2020 Jul 17.
10
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.不同 GLP-1 受体激动剂与胃肠道不良反应的关联性：基于 FDA 不良事件报告系统数据库的真实世界药物不良反应比例性研究。
Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. doi: 10.3389/fendo.2022.1043789. eCollection 2022.

引用本文的文献

1
The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders.胰高血糖素样肽-1受体激动剂在神经认知障碍中的治疗作用及机制
Ther Adv Neurol Disord. 2025 Apr 17;18:17562864251332035. doi: 10.1177/17562864251332035. eCollection 2025.
2
Intestinal stearoyl-coenzyme A desaturase-inhibition improves obesity-associated metabolic disorders.肠道硬脂酰辅酶A去饱和酶抑制可改善肥胖相关的代谢紊乱。
Acta Pharm Sin B. 2025 Feb;15(2):892-908. doi: 10.1016/j.apsb.2024.11.022. Epub 2024 Dec 2.
3
Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide.

本文引用的文献

1
The 'breakthrough' obesity drugs that have stunned researchers.那些令研究人员震惊的“突破性”肥胖药物。
Nature. 2023 Jan;613(7942):16-18. doi: 10.1038/d41586-022-04505-7.
2
The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel.双重 GLP-1 和 GLP-2 受体激动剂 dapiglutide 可促进小鼠短肠的屏障功能。
Ann N Y Acad Sci. 2022 Aug;1514(1):132-141. doi: 10.1111/nyas.14791. Epub 2022 May 17.
3
Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel.
低剂量替尔泊肽相关的急性功能性胃出口梗阻
Cureus. 2025 Jan 27;17(1):e78090. doi: 10.7759/cureus.78090. eCollection 2025 Jan.
4
Astragalus Mongholicus Polysaccharides Alleviate Kidney Injury in Rats with Type 2 Diabetes Through Modulation of Oxidation, Inflammation, and Gut Microbiota.黄芪多糖通过调节氧化、炎症和肠道微生物群减轻2型糖尿病大鼠的肾损伤
Int J Mol Sci. 2025 Feb 10;26(4):1470. doi: 10.3390/ijms26041470.
5
Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.炎症性肠病患者超重和肥胖的管理
Gastroenterol Hepatol (N Y). 2024 Dec;20(12):712-722.
6
Does Incretin Agonism Have Sustainable Efficacy?肠促胰岛素激动剂是否具有可持续疗效？
Cells. 2024 Nov 7;13(22):1842. doi: 10.3390/cells13221842.
7
Tirzepatide-Associated Colonic Ischemia.替尔泊肽相关性结肠缺血
ACG Case Rep J. 2024 Nov 6;11(11):e01551. doi: 10.14309/crj.0000000000001551. eCollection 2024 Nov.
8
Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum.肥胖相关2型糖尿病的手术或药物治疗——一个日益棘手的临床难题。
World J Diabetes. 2024 Oct 15;15(10):2036-2040. doi: 10.4239/wjd.v15.i10.2036.
9
Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide.在不恰当使用司美格鲁肽的患者中观察到食物引起的小肠梗阻。
Diabetol Int. 2024 Sep 9;15(4):850-854. doi: 10.1007/s13340-024-00751-4. eCollection 2024 Oct.
10
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.GLP-1 激动剂在 2 型糖尿病和肥胖症治疗中与严重不良事件相关的综述。
Pharmacol Rep. 2024 Oct;76(5):981-990. doi: 10.1007/s43440-024-00629-x. Epub 2024 Aug 2.
度拉糖肽，一种新型双重 GLP-1 和 GLP-2 受体激动剂，可减轻短肠综合征小鼠模型中的肠道功能不全。
JPEN J Parenter Enteral Nutr. 2022 Jul;46(5):1107-1118. doi: 10.1002/jpen.2286. Epub 2021 Nov 18.
4
Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.基于肠降血糖素的药物与 2 型糖尿病患者肠梗阻风险。
Clin Pharmacol Ther. 2022 Jan;111(1):272-282. doi: 10.1002/cpt.2430. Epub 2021 Oct 16.
5
A Role for GLP-1 in Treating Hyperphagia and Obesity.GLP-1 在治疗暴食症和肥胖中的作用。
Endocrinology. 2020 Aug 1;161(8). doi: 10.1210/endocr/bqaa093.
6
Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.基于肠降血糖素的药物与肠梗阻：一项药物警戒研究。
Therapie. 2020 Nov-Dec;75(6):641-647. doi: 10.1016/j.therap.2020.02.024. Epub 2020 May 11.
7
Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study.利拉鲁肽治疗对短肠综合征患者空肠造口排出量的影响：一项开放标签的初步研究。
JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):112-121. doi: 10.1177/0148607116672265. Epub 2017 Dec 11.
8
Gut hormones in the treatment of short-bowel syndrome and intestinal failure.肠道激素在短肠综合征和肠衰竭治疗中的应用
Curr Opin Endocrinol Diabetes Obes. 2015 Feb;22(1):14-20. doi: 10.1097/MED.0000000000000120.
9
The central GLP-1: implications for food and drug reward.中枢 GLP-1：对食物和药物奖赏的影响。
Front Neurosci. 2013 Oct 14;7:181. doi: 10.3389/fnins.2013.00181.
10
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?基于肠促胰岛素的治疗方法的临床应用的批判性分析：GLP-1 治疗方法安全吗？
Diabetes Care. 2013 Jul;36(7):2118-25. doi: 10.2337/dc12-2713. Epub 2013 May 3.